# The Reference in Prevention in Rabbits

**DVM, PhD Marta Busquet Solé** 

**November 2012** 




## **HIPRA: The Reference in Prevention in Rabbits**



- Experts in the development and commercialisation of rabbit vaccines.
- Leading the market for RHD and Myxomatosis in the most important markets in the EU.


# **Spanish Market Myxomatosis**



(Veterindustria, 2010)




# **Spanish Market RHD**



(Veterindustria, 2010)



# **French Market RHD**





## **HIPRA:** The Reference in Prevention in Rabbits

#### CUNIPRAVAC® RHD

- Inactivated vaccine against rabbit haemorrhagic disease
- Oil based adjuvant (greater and longer lasting immunity)
- Subcutaneous administration (0.5 ml/rabbit)




#### MIXOHIPRA® H


- Live homologous vaccine against myxomatosis
- Freeze-dried fraction + solvent
- Subcutaneous administration (0.5 ml/rabbit), or intradermically (0.1 ml/rabbit) by Dermojet system

## **HIPRA: The Reference in Prevention in Rabbits**

#### **GENERAL VACCINAL PLAN FOR BREEDERS**



#### **GENERAL VACCINAL PLAN FOR FATTENING**







- Inactivated vaccine to prevent enterotoxemia
- Composition: (per 2 ml)

Clostridium perfringens (types B, C and D)
>10 IU of β antitoxin/ml of serum and
>5 IU of ε-antitoxin/ml of serum:

Clostridium novyi type B > 3.5 IU of  $\alpha$ -antitoxin/ml of serum; Clostridium septicum >2.5 IU of  $\alpha$  -antitoxin/ml of serum; Clostridium tetani > 2.5 IU of antitoxin/ml of serum Clostridium chauvoei 100% protection\* (anaculture) Adjuvant

I.M or S.C administration (0.5 ml/rabbit)







- Breeding rabbits:
  - From 2 months of age: apply 1 dose + a revaccination dose with an interval of 21 days.
  - Booster dose every 4 6 months.
- Rabbits for fattening:
  - Before weaning at a dose of 0.2 ml / animal every 20 - 25 days.





# **Pharmaceuticals for Rabbits**



# **Hormonal range**

### Gonadorelin, in injectable solution

- Indications: Ovulation induction.
- Administration route: Intramuscular.
  - 0.2 ml/animal (equivalent to 20 μg of gonadorelin/animal)
- Withdrawal time: 0 days.
- Packaging: 10 ml and 20 ml vial.







# **Antibiotics range**

#### **Composition:**

Enrofloxacin 100 mg/ml + excipient

#### Indications for use:

Rabbits (only in Europe): Pasteurellosis

#### **Posology and method administration:**

Rabbits: 0.1 ml/L kg b.w./day, for 5 days (= 10 mg enro/kg b.w./day)

#### Withdrawal period:

Meat: 2 days

#### **Nature and contents of container:**


Bottle 1000 ml - 5000 ml







# **MEGLUXIN®**: Pharmacodynamic properties



MEGLUXIN<sup>®</sup> is Flunixin meglumine 5% in injectable solution.

Is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties.

Flunixin meglumine acts as a non-selective and reversible inhibitor of cyclooxygenase (COX).

- COX is an enzyme that converts arachidonic acid to unstable cyclic endoperoxides that are then transformed into prostaglandins, prostacyclin and thromboxane.
- Some of these prostanoids, such as prostaglandins, are involved in the physiopathological mechanisms of inflammation pain and fever; thus, its inhibition would responsible for its therapeutic effects.

## Indications, dose and administration route

Rabbits

Offlabel use!

- Indications:
  - Anti-inflammatory, analgesic, antipyretic
- Dosage and route:
  - IM or SC
  - 1.1 mg of flunixin (meglumine)/kg b.w. (equivalent to 0.22 ml MEGLUXIN/10 kg b.w.). One or two injections may be administered 12 hours apart.

Antipyretic, analgesic and anti-inflammatory properties of different molecules:

	ANTIPYRETIC activity	ANALGESIC activity	ANTI-INFLAMMATORY activity	ANTIHISTAMINIC activity
KETOPROFEN		00	000	12
MELOXICAM		00	000	
TOLFENAMIC acid	•	000	0000	
DEXAMETHASONE	## ## ## ## ## ## ## ## ## ## ## ## ##		0000	0000
MEGLUXIN <sup>®</sup>		•••	••••	

